Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (8 quarters reported)
$131M in Q4 2014 → $30.8M now. Hover for any quarter.
As reported for the quarter ended September 30, 2016. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| IP Inotek Pharmaceuticals Corporation | 100.0% | Unchanged | 3,243,709 | $30.8M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.
quarter ended September 30, 2016 · filed November 14, 2016
No position changes this quarter.
quarter ended June 30, 2016 · filed August 15, 2016
No position changes this quarter.
quarter ended March 31, 2016 · filed May 03, 2016
No position changes this quarter.
quarter ended December 31, 2015 · filed February 09, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| ZP Zs Pharma Inc. | Exited | −2,576,723 | −$169M | — |
quarter ended September 30, 2015 · filed November 16, 2015
No position changes this quarter.
quarter ended June 30, 2015 · filed August 14, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CT Cara Therapeutics Inc. | Exited | −596,082 | −$5.99M | — |
| PT Proteon Therapeutics Inc. | Exited | −325,727 | −$3.79M | — |
quarter ended March 31, 2015 · filed May 13, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IP Inotek Pharmaceuticals Corporation | New | +3,243,709 | +$17.6M | 12.9% |
| C Cempra Inc | Exited | −390,144 | −$9.17M | — |
| CT Cara Therapeutics Inc. | Trimmed | −555,812 | −$5.59M | 4.4% |
Loading...
